Type 1 Diabetes Mellitus Clinical Trial
Official title:
Evaluating the Dynamics of Insulin and Non-insulin Mediated Effects on Glucose During Aerobic Exercise in Subjects With Type 1 Diabetes
People with type 1 diabetes often find exercise very difficult to manage, because of the high
risk for low blood glucose levels. This can occur very quickly once exercise starts and
presents many risks for subjects, such as severe symptoms, confusion, passing out, seizures,
and even coma or death in very severe cases. Preventing low blood glucose levels during and
after exercise is important because physical exercise is a key component of managing
diabetes. It is often hard to correctly adjust insulin infusion rates or doses before
exercise as the relationship between exercise and changes in glucose levels in those who have
type 1 diabetes is still not fully understood. Therefore, the investigators propose this
study to further our understanding in this area.
This study is designed to help separate the effects of insulin from those of muscle work
(non-insulin effects) on the changes in blood glucose levels during aerobic exercise. The
main hypothesis is that the non-insulin effects occur quickly during exercise and account for
the rapid change in blood glucose levels once aerobic exercise begins. These effects can be
separated from the slower changes in insulin sensitivity that occur because of exercise, and
which account for reduced insulin demand even after exercise has stopped. The investigators
will investigate the effects of both moderate and intense aerobic exercise at different
levels of insulin in the body to help separate the insulin and non-insulin effects.
The investigators wish to recruit 26 subjects to take part in this study. Subjects will be
randomly divided into two groups, with 13 in each group. Group 1 will undergo moderate
aerobic exercise, while group 2 will undergo intense aerobic exercise. Each subject will
repeat the exercise study three times on three separate days at least 2 weeks apart, while
having insulin infused at a low, a medium, and a high rate. Subjects will have an IV line
placed in each arm, one for drawing blood relatively frequently during the study, and another
for infusion of insulin, glucose, and a special glucose tracer (non-radioactive). Each study
lasts about 9 hours.
Information from this study will be used to help develop a mathematical model of how glucose
changes during exercise in type 1 diabetes. Such a model of type 1 diabetes and exercise will
be very useful for adjusting insulin doses in patients who use multiple daily injections of
insulin, and can help to guide an automated insulin delivery system, such as the artificial
pancreas.
Diabetes mellitus afflicts close to 10% of our population and 5% of those with diabetes have
type 1, which is defined by an absolute deficiency of insulin. The need for managing diabetes
is critical, given the economic burden of this disease, with over $175 billion dollars in
direct health care costs, and almost another $70 billion in indirect costs for disability and
work loss. The personal impact is equally as important for people with this disease, as
diabetes mellitus is the leading cause of blindness, the need for kidney dialysis, and
non-traumatic amputations in the United States. Type 2 diabetes is associated with reduced
insulin sensitivity and the metabolic syndrome, and dietary modification and exercise are
important components in the management of underlying insulin resistance. However, these
lifestyle strategies are also important in type 1 diabetes for many reasons: 1) type 1
diabetes subjects now live into adulthood, when insulin resistance and obesity become factors
for glycemic control, 2) latent autoimmune diabetes of adulthood (LADA) represents a "mixed"
form of autoimmune diabetes where some type 2 diabetes characteristics such as insulin
resistance can exist, and 3) dietary modification and exercise remain effective means for
management of acute hyperglycemia and, in the longer term, HbA1c, potentially reducing the
risk of microvascular complications. Therefore, the need for exercise is still evident in
subjects with type 1 diabetes to maintain good glycemic control and to prevent complications
from developing. However, exercise is challenging for people with T1D to manage. Exercise
causes increased insulin sensitivity along with rapid uptake of glucose by muscle and other
tissues within the body, leading to a sharp decline in glucose levels and hypoglycemia as
shown by other groups as well as ours.
Without adjustments in insulin for exercise, hypoglycemia is common in persons with type 1
diabetes. In a study of 48 individuals with T1D, with no adjustments to insulin, who exercise
for 60 min at a moderate intensity, glucose levels dropped on average by 40%, with 52% of
subjects falling to 70 mg/dL or below. Despite this clear need for insulin adjustments for
exercise, there are no uniform recommendations on how to dose insulin around the time of
exercise. In 2006, the DirecNet Study Group published a study on the impact of suspending
basal insulin at the start of exercise in 40 children with type 1 diabetes on insulin pump
therapy. This intervention significantly reduced hypoglycemia (from 43% to 16%), but much
more commonly resulted in hyperglycemia (increased from 4% to 23%). Schiavon and Cobelli et
al addressed this issue of how to best adjust insulin for exercise using in silico
simulations. Adjusting insulin doses in the in silico environment decreased hypoglycemia from
88% to 16% of patients when a universal adjustment was applied, and to 4% when an individual
adjustment was applied.
The study described within this protocol is designed to disambiguate the impact of exercise
on insulin and non-insulin mediated effects on glycemic control. To achieve this, the
investigators will perform a series of stable glucose tracer studies in which subjects will
be fasting for about 8 hours and will undergo aerobic exercise at a moderate and intense
level for 45 minutes while insulin rates are clamped at a low (subject's basal rate), medium
(basal x 1.5), and high (basal x 3) insulin infusion rate. Subject's basal rates will be
obtained from injected basal insulin amounts, such as NPH/glargine/detemir, or basal rates in
those who use insulin pumps and will be adjusted for the HbA1c, as described in the OHSU AP
system. Di-deuterated glucose (6,6-2H2-glucose) which is not radioactive and which can be
metabolized via usual pathways in the human body will be the stable tracer. Each subject per
arm will undergo 3 10-hour studies while blood glucose, insulin, and glucagon levels are
captured throughout the study, and catecholamine and fatty acid levels are captured during
and just after the exercise period, as outlined below. Glucose tracer levels will be measured
at OHSU through the Bioanalytical Shared Resource/PK core lab, and calculation of rate of
appearance (Ra) and rate of disappearance (Rd) of glucose will be performed by our colleagues
at McGill University using a non-steady state model of glucose dynamics.
The data obtained from this study will inform an updated model of glucose regulation in type
1 diabetes, providing exercise as an input to the model, which will be utilized in a model
predictive control (MPC) system for managing type 1 diabetes. Such a system can be used to
deliver insulin and/or glucagon to manage glycemic changes during and outside of exercise.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A |